Skip to main content

DESARROLLO, VALIDACION E IMPLEMENTACION DE NUEVOS TESTS BIOMARCADORES PARA DEMENCIAS NEURODEGENERATIVAS. PAPEL EN DIAGNOSIS, PROGNOSIS Y SEGUIMINETO DE LA ENFERMEDAD

PI19/00144

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre CIBER DE ENFERMEDADES NEURODEGENERATIVAS
Execution centre HOSPITAL DE BELLVITGE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

TREM2 expression in the brain and biological fluids in prion diseases

  • Diaz‑Lucena, Daniela
  • Kruse, Niels
  • Thüne, Katrin
  • Schmitz, Matthias
  • Villar‑Piqué, Anna
  • da Cunha, Jose Eriton Gomes
  • Hermann, Peter
  • López‑Pérez, Óscar
  • Andrés‑Benito, Pol
  • Ladogana, Anna
  • Calero, Miguel
  • Vidal, Enric
  • Riggert, Joachim
  • Pineau, Hailey
  • Sim, Valerie
  • Zetterberg, Henrik
  • Blennow, Kaj
  • del Río, Jose Antonio
  • Marín‑Moreno, Alba
  • Espinosa, Juan Carlos
  • Torres, Juan María
  • Sánchez‑Valle, Raquel
  • Mollenhauer, Brit
  • Ferrer, Isidre
  • Zerr, Inga
  • Llorens, Franc
Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune cell surface receptor that regulates microglial function and is involved in the pathophysiology of several neurodegenerative diseases. Its soluble form (sTREM2) results from shedding of the TREM2 ectodomain. The role of TREM2 in prion diseases, a group of rapidly progressive dementias remains to be elucidated. In the present study, we analysed the expression of TREM2 and its main sheddase ADAM10 in the brain of sporadic Creutzfeldt-Jakob disease (sCJD) patients and evaluated the role of CSF and plasma sTREM2 as a potential diagnostic marker of prion disease. Our data indicate that, compared to controls, TREM2 is increased in sCJD patient brains at the mRNA and protein levels in a regional and subtype dependent fashion, and expressed in a subpopulation of microglia. In contrast, ADAM10 is increased at the protein, but not the mRNA level, with a restricted neuronal expression. Elevated CSF sTREM2 is found in sCJD, genetic CJD with mutations E200K and V210I in the prion protein gene (PRNP), and iatrogenic CJD, as compared to healthy controls (HC) (AUC = 0.78–0.90) and neurological controls (AUC = 0.73–0.85), while CSF sTREM2 is unchanged in fatal familial insomnia. sTREM2 in the CSF of cases with Alzheimer’s disease, and multiple sclerosis was not significantly altered in our series. CSF sTREM2 concentrations in sCJD are PRNP codon 129 and subtype-related, correlate with CSF 14-3-3 positivity, total-tau and YKL-40, and increase with disease progression. In plasma, sTREM2 is increased in sCJD compared with HC (AUC = 0.80), displaying positive correlations with plasma total-tau, neurofilament light, and YKL-40. We conclude that comparative study of TREM2 in brain and biological fluids of prion diseases reveals TREM2 to be altered in human prion diseases with a potential value in target engagement, patient stratification, and disease monitoring., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

TREM2 expression in the brain and biological fluids in prion diseases

  • Diaz-Lucena, Daniela
  • Kruse, Niels
  • Thüne, Katrin
  • Schmitz, Matthias
  • Villar-Piqué, Anna
  • Cunha, Jose Eriton Gomes da
  • Hermann, Peter
  • López-Pérez, Óscar
  • Andrés-Benito, Pol
  • Ladogana, Anna
  • Calero, Miguel
  • Vidal, Enric
  • Riggert, Joachim
  • Pineau, Hailey
  • Sim, Valerie
  • Zetterberg, Henrik
  • Blennow, Kaj
  • Del Río, J. A.
  • Marín-Moreno, Alba
  • Espinosa, Juan Carlos
  • Torres, Juan María
  • Sánchez-Valle, Raquel
  • Mollenhauer, Brit
  • Ferrer, Isidre
  • Zerr, I.
  • Llorens, Franc
19 Pág. Centro de Investigación en Sanidad Animal (CISA), Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune cell surface receptor that regulates microglial function and is involved in the pathophysiology of several neurodegenerative diseases. Its soluble form (sTREM2) results from shedding of the TREM2 ectodomain. The role of TREM2 in prion diseases, a group of rapidly progressive dementias remains to be elucidated. In the present study, we analysed the expression of TREM2 and its main sheddase ADAM10 in the brain of sporadic Creutzfeldt-Jakob disease (sCJD) patients and evaluated the role of CSF and plasma sTREM2 as a potential diagnostic marker of prion disease. Our data indicate that, compared to controls, TREM2 is increased in sCJD patient brains at the mRNA and protein levels in a regional and subtype dependent fashion, and expressed in a subpopulation of microglia. In contrast, ADAM10 is increased at the protein, but not the mRNA level, with a restricted neuronal expression. Elevated CSF sTREM2 is found in sCJD, genetic CJD with mutations E200K and V210I in the prion protein gene (PRNP), and iatrogenic CJD, as compared to healthy controls (HC) (AUC = 0.78-0.90) and neurological controls (AUC = 0.73-0.85), while CSF sTREM2 is unchanged in fatal familial insomnia. sTREM2 in the CSF of cases with Alzheimer's disease, and multiple sclerosis was not significantly altered in our series. CSF sTREM2 concentrations in sCJD are PRNP codon 129 and subtype-related, correlate with CSF 14-3-3 positivity, total-tau and YKL-40, and increase with disease progression. In plasma, sTREM2 is increased in sCJD compared with HC (AUC = 0.80), displaying positive correlations with plasma total-tau, neurofilament light, and YKL-40. We conclude that comparative study of TREM2 in brain and biological fluids of prion diseases reveals TREM2 to be altered in human prion diseases with a potential value in target engagement, patient stratification, and disease monitoring., We thank the HUB-ICO-IDIBELL-Biobank and the CERCA Programme of the Generalitat de Catalunya for institutional support. This study was funded by the Instituto Carlos III (Grants Number CP16/00041 and PI19/00144) to FL. This project was also funded by la Fundació La Marató de TV3 (Grants No. 201821-30, 201821-31and 201821-32 to FL, JCE and EV, respectively) and by the Fondo Europeo de Desarrollo Regional (FEDER) through the Interreg V-A España-Francia-Andorra (POCTEFA 2014–2020) programme (at 65%) to IF. AVP is supported by the Beatriu de Pinós programme (2018-BP-00129) from the Ministry of Business and nowledge of the Government of Catalonia, and cofunded by the EU Horizon 2020 programme under an MSCA grant agreement (801370). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915), the Swedish State Support for Clinical Research (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), and the European Union Joint Programme for Neurodegenerative Disorders (JPND2019-466-236). AL is supported by the Ministero della Salute, Italy, for the national surveillance of Creutzfeldt-Jakob disease. This research was also supported in part by the Alberta Synergies in Alzheimer’s and Related Disorders (SynAD) programme which is funded by the Alzheimer Society of Alberta and Northwest Territories through their Hope for Tomorrow programme and the University Hospital Foundation. SynAD operates in partnership with the Neuroscience and Mental Health Institute at the University of Alberta. JADR was supported by grants from the Spanish Ministry of Science, Innovation and Universities (MICINN/FEDER) (RTI2018-099773-B-I00), the CERCA Programme, and by the Commission for Universities and Research of the Department of Innovation, Universities, and Enterprise of the Generalitat de Catalunya (SGR2017-648) and CIBERNED (CMED2018-2), Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Bambi and chga in prion diseases: neuropathological assessment and potential role as disease biomarkers

  • López-Pérez, Óscar
  • Bernal-Martín, Marcos
  • Hernaiz, Adelaida
  • Llorens, Franc
  • Betancor, Marina
  • Otero,Alicia
  • Toivonen, Janne Markus
  • Zaragoza, Pilar
  • Zerr, Inga
  • Badiola, Juan José
  • Bolea, Rosa
  • Martín-Burriel, Inmaculada.
Prion diseases affect both animals and humans. Research in the natural animal model of the disease could help in the understanding of neuropathological mechanisms and in the development of biomarkers for human pathologies. For this purpose, we studied the expression of 10 genes involved in prion propagation in vitro in the central nervous system of scrapie-infected sheep. Dysregulated genes (BAMBI and CHGA) were further analysed in a transgenic murine model (Tg338) of scrapie, and their protein distribution was determined using immunohistochemistry and Western blot. Their potential as biomarkers was finally assessed using enzyme-linked immunosorbent assay (ELISA) in cerebrospinal fluid (CSF) of scrapie sheep and Creutzfeldt-Jakob disease (CJD) patients. Protein BAMBI was upregulated in highly affected brain areas and CHGA was overexpressed along the brain in both models. Moreover, BAMBI and CHGA immunostaining scores strongly correlated with spongiosis and microgliosis in mice. Finally, levels of BAMBI were significantly higher in the CSF of clinical sheep and CJD patients. In addition to their potential as biomarkers, our work confirms the role of BAMBI and CHGA in prion neuropathology in vivo, but besides prion replication, they seem to be involved in the characteristic neuroinflammatory response associated to prion infection. Las enfermedades priónicas afectan tanto a los animales como a los humanos. La investigación en el modelo animal natural de la enfermedad podría ayudar en la comprensión de los mecanismos neuropatológicos y en el desarrollo de biomarcadores para patologías humanas. Para ello, estudiamos la expresión de 10 genes implicados en la propagación de priones in vitro en el sistema nervioso central de ovejas infectadas con scrapie. Genes desregulados ( BAMBI y CHGA) se analizaron más a fondo en un modelo murino transgénico (Tg338) de tembladera, y su distribución de proteínas se determinó mediante inmunohistoquímica y transferencia Western. Finalmente, se evaluó su potencial como biomarcadores utilizando un ensayo inmunoabsorbente ligado a enzimas (ELISA) en líquido cefalorraquídeo (LCR) de ovejas con tembladera y pacientes con enfermedad de Creutzfeldt-Jakob (ECJ). La proteína BAMBI se reguló positivamente en áreas cerebrales muy afectadas y CHGA se sobreexpresó a lo largo del cerebro en ambos modelos. Además, las puntuaciones de inmunotinción de BAMBI y CHGA se correlacionaron fuertemente con la espongiosis y la microgliosis en ratones. Finalmente, los niveles de BAMBI fueron significativamente más altos en el líquido cefalorraquídeo de ovejas clínicas y pacientes con ECJ. Además de su potencial como biomarcadores, nuestro trabajo confirma el papel de BAMBI y CHGA en la neuropatología priónica in vivo, pero además de la replicación priónica,
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

An Update on Autophagy in Prion Diseases

  • López-Pérez, O.
  • Badiola, J.J.
  • Bolea, R.
  • Ferrer, I.
  • Llorens, F.
  • Martín-Burriel, I.
Autophagy is a dynamic intracellular mechanism involved in protein and organelle turnover through lysosomal degradation. When properly regulated, autophagy supports normal cellular and developmental processes, whereas defects in autophagic degradation have been associated with several pathologies, including prion diseases. Prion diseases, or transmissible spongiform encephalopathies (TSE), are a group of fatal neurodegenerative disorders characterized by the accumulation of the pathological misfolded isoform (PrPSc) of the physiological cellular prion protein (PrPc) in the central nervous system. Autophagic vacuoles have been described in experimental models of TSE and in the natural disease in humans. The precise connection of this process with prion-related neuropathology, or even whether autophagy is completely beneficial or pathogenic during neurodegeneration, is poorly understood. Thus, the biological role of autophagy in these diseases is still open to debate. During the last years, researchers have used a wide range of morphological, genetic and biochemical methods to monitor and manipulate the autophagic pathway and thus determine the specific role of this process in TSE. It has been suggested that PrPc could play a crucial role in modulating the autophagic pathway in neuronal cells, and the presence of abnormal autophagic activity has been frequently observed in several models of TSE both in vitro and in vivo, as well as in human prion diseases. Altogether, these findings suggest that autophagy is implicated in prion neuropathology and points to an impairment or failure of the process, potentially contributing to the pathogenesis of the disease. Additionally, autophagy is now emerging as a host defense response in controlling prion infection that plays a protective role by facilitating the clearance of aggregation-prone proteins accumulated within neurons. Since autophagy is one of the pathways of PrPSc degradation, and drug-induced stimulation of autophagic flux (the dynamic process of autophagic degradation activity) produces anti-prion effects, new treatments based on its activation have been tested to develop therapeutic strategies for prion diseases. In this review, we summarize previous and recent findings concerning the role of autophagy in TSE.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

TREM2 expression in the brain and biological fluids in prion diseases

  • Diaz‑Lucena, Daniela
  • Kruse, Niels
  • Thüne, Katrin
  • Schmitz, Matthias
  • Villar‑Piqué, Anna
  • da Cunha, Jose Eriton Gomes
  • Hermann, Peter
  • López‑Pérez, Óscar
  • Andrés‑Benito, Pol
  • Ladogana, Anna
  • Calero, Miguel
  • Vidal, Enric
  • Riggert, Joachim
  • Pineau, Hailey
  • Sim, Valerie
  • Zetterberg, Henrik
  • Blennow, Kaj
  • del Río, Jose Antonio
  • Marín‑Moreno, Alba
  • Espinosa, Juan Carlos
  • Torres, Juan María
  • Sánchez‑Valle, Raquel
  • Mollenhauer, Brit
  • Ferrer, Isidre
  • Zerr, Inga
  • Llorens, Franc
Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune cell surface receptor that regulates microglial function and is involved in the pathophysiology of several neurodegenerative diseases. Its soluble form (sTREM2) results from shedding of the TREM2 ectodomain. The role of TREM2 in prion diseases, a group of rapidly progressive dementias remains to be elucidated. In the present study, we analysed the expression of TREM2 and its main sheddase ADAM10 in the brain of sporadic Creutzfeldt-Jakob disease (sCJD) patients and evaluated the role of CSF and plasma sTREM2 as a potential diagnostic marker of prion disease. Our data indicate that, compared to controls, TREM2 is increased in sCJD patient brains at the mRNA and protein levels in a regional and subtype dependent fashion, and expressed in a subpopulation of microglia. In contrast, ADAM10 is increased at the protein, but not the mRNA level, with a restricted neuronal expression. Elevated CSF sTREM2 is found in sCJD, genetic CJD with mutations E200K and V210I in the prion protein gene (PRNP), and iatrogenic CJD, as compared to healthy controls (HC) (AUC = 0.78–0.90) and neurological controls (AUC = 0.73–0.85), while CSF sTREM2 is unchanged in fatal familial insomnia. sTREM2 in the CSF of cases with Alzheimer’s disease, and multiple sclerosis was not significantly altered in our series. CSF sTREM2 concentrations in sCJD are PRNP codon 129 and subtype-related, correlate with CSF 14-3-3 positivity, total-tau and YKL-40, and increase with disease progression. In plasma, sTREM2 is increased in sCJD compared with HC (AUC = 0.80), displaying positive correlations with plasma total-tau, neurofilament light, and YKL-40. We conclude that comparative study of TREM2 in brain and biological fluids of prion diseases reveals TREM2 to be altered in human prion diseases with a potential value in target engagement, patient stratification, and disease monitoring., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

TREM2 expression in the brain and biological fluids in prion diseases

  • Diaz-Lucena, Daniela
  • Kruse, Niels
  • Thüne, Katrin
  • Schmitz, Matthias
  • Villar-Piqué, Anna
  • da Cunha, Jose Eriton Gomes
  • Hermann, Peter
  • López-Pérez, Óscar
  • Andrés-Benito, P.|||0000-0003-3000-0338
  • Ladogana, Anna
  • Calero, Miguel|||0000-0001-5366-3324
  • Vidal Barba, Enric|||0000-0002-4965-3286
  • Riggert, Joachim
  • Pineau, Hailey
  • Sim, Valerie
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Rio, Jose Antonio del|||0000-0002-5214-4909
  • Marín-Moreno, Alba|||0000-0002-4023-6398
  • Espinosa, Juan Carlos
  • Torres, Juan María
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Mollenhauer, Brit|||0000-0001-8437-3645
  • Ferrer, Isidro|||0000-0001-9888-8754
  • Zerr, Inga
  • Llorens, Franc|||0000-0002-9756-7497
Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune cell surface receptor that regulates microglial function and is involved in the pathophysiology of several neurodegenerative diseases. Its soluble form (sTREM2) results from shedding of the TREM2 ectodomain. The role of TREM2 in prion diseases, a group of rapidly progressive dementias remains to be elucidated. In the present study, we analysed the expression of TREM2 and its main sheddase ADAM10 in the brain of sporadic Creutzfeldt-Jakob disease (sCJD) patients and evaluated the role of CSF and plasma sTREM2 as a potential diagnostic marker of prion disease. Our data indicate that, compared to controls, TREM2 is increased in sCJD patient brains at the mRNA and protein levels in a regional and subtype dependent fashion, and expressed in a subpopulation of microglia. In contrast, ADAM10 is increased at the protein, but not the mRNA level, with a restricted neuronal expression. Elevated CSF sTREM2 is found in sCJD, genetic CJD with mutations E200K and V210I in the prion protein gene (PRNP), and iatrogenic CJD, as compared to healthy controls (HC) (AUC=0.78-0.90) and neurological controls (AUC=0.73-0.85), while CSF sTREM2 is unchanged in fatal familial insomnia. sTREM2 in the CSF of cases with Alzheimer's disease, and multiple sclerosis was not signifcantly altered in our series. CSF sTREM2 concentrations in sCJD are PRNP codon 129 and subtype-related, correlate with CSF 14-3-3 positivity, total-tau and YKL-40, and increase with disease progression. In plasma, sTREM2 is increased in sCJD compared with HC (AUC=0.80), displaying positive correlations with plasma total-tau, neuroflament light, and YKL-40. We conclude that comparative study of TREM2 in brain and biological fuids of prion diseases reveals TREM2 to be altered in human prion diseases with a potential value in target engagement, patient stratifcation, and disease monitoring.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases

  • Lidón Gil, Laia|||0000-0002-2083-3515
  • Urrea, Laura
  • Llorens, Franc|||0000-0002-9756-7497
  • Gil, Vanessa|||0000-0002-7782-5575
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Diez-Fairen, Monica|||0000-0003-1882-0309
  • Aguilar Barberà, Miquel
  • Pastor, Pau|||0000-0002-7493-8777
  • Zerr, Inga
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Vidal Barba, Enric|||0000-0002-4965-3286
  • Gavín, Rosalina|||0000-0003-1982-2162
  • Ferrer, Isidro|||0000-0001-9888-8754
  • Rio, Jose Antonio del|||0000-0002-5214-4909
Reelin is an extracellular glycoprotein that modulates neuronal function and synaptic plasticity in the adult brain. Decreased levels of Reelin activity have been postulated as a key factor during neurodegeneration in Alzheimer's disease (AD) and in aging. Thus, changes in levels of full-length Reelin and Reelin fragments have been revealed in cerebrospinal fluid (CSF) and in post-mortem brains samples of AD patients with respect to non-AD patients. However, conflicting studies have reported decreased or unchanged levels of full-length Reelin in AD patients compared to control (nND) cases in post-mortem brains and CSF samples. In addition, a compelling analysis of Reelin levels in neurodegenerative diseases other than AD is missing. In this study, we analyzed brain levels of RELN mRNA and Reelin protein in post-mortem frontal cortex samples from different sporadic AD stages, Parkinson's disease with dementia (PDD), and Creutzfeldt-Jakob disease (sCJD), obtained from five different Biobanks. In addition, we measured Reelin protein levels in CSF samples of patients with mild cognitive impairment (MCI), dementia, or sCJD diagnosis and a group of neurologically healthy cases. The results indicate an increase in RELN mRNA in the frontal cortex of advanced stages of AD and in sCJD(I) compared to controls. This was not observed in PDD and early AD stages. However, Reelin protein levels in frontal cortex samples were unchanged between nND and advanced AD stages and PDD. Nevertheless, they decreased in the CSF of patients with dementia in comparison to those not suffering with dementia and patients with MCI. With respect to sCJD, there was a tendency to increase in brain samples in comparison to nND and to decrease in the CSF with respect to nND. In conclusion, Reelin levels in CSF cannot be considered as a diagnostic biomarker for AD or PDD. However, we feel that the CSF Reelin changes observed between MCI, patients with dementia, and sCJD might be helpful in generating a biomarker signature in prodromal studies of unidentified dementia and sCJD.